Symphony Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Symphony Asset Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-3,000	Closed	-$303K	–	482
2014 Q4	$303K	Buy	+3,000	New	+$292K	0.04%	337
2014 Q1	–	Sell	-39,000	Closed	-$2.95M	–	435
2013 Q4	$2.95M	Buy	+39,000	New	+$2.77M	0.22%	99

Other funds holding IBB

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Symphony Asset Management's IBB Position: Q2 2015 in Review

Symphony Asset Management sold out of iShares Biotechnology ETF (IBB) in Q2 2015, closing a stake of 3,000 shares — an estimated $343K sold.

Symphony Asset Management first reported a position in IBB in Q1 2015 and held it in 1 quarter. The position peaked at $343K in Q1 2015. 419 funds tracked by Wall St. Rank hold IBB as of Q2 2015.

Symphony Asset Management reported no remaining iShares Biotechnology ETF position as of Q2 2015 after selling out during the quarter.
Symphony Asset Management sold 3,000 iShares Biotechnology ETF shares in Q2 2015, an estimated $343K.
Symphony Asset Management first reported a position in iShares Biotechnology ETF in Q1 2015 and held it in 1 quarter.
Symphony Asset Management's iShares Biotechnology ETF position peaked at $343K in Q1 2015.
419 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2015.

Based on Symphony Asset Management's 13F filing for Q2 2015, filed 12 Aug 2015.